1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
DocMorris AG

DocMorris AG

DOCM.SW
DocMorris AGCH flagSwiss Exchange
9.09
CHF
-0.16
- -
444.40MMarket Cap
DocMorris AG
DOCM.SW
(Swiss Exchange)

Recent

price

9.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
53.02
75.3
80.66
132.45
133.22
121.04
95.49
92.76
93.63
77.04
80.13
88.14
42.54
40.89
42.47
Revenue per Share
- -
0.43
1.34
0.95
-2.25
1.04
0.5
-1.39
-3.42
-3.02
-2.98
-7.36
-11.52
-7.82
3.47
-4.06
Basic EPS, GAAP
- -
0.95
-0.04
2.44
-1.26
-1.26
0.53
-3.66
-4.14
-5.02
-7.05
-6.91
-9.91
-6.57
-5.01
-2.31
Free Cash Flow per Basic Share
- -
0.62
0.58
0.23
0.22
- -
0.28
0.18
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
6.45
10.38
11.17
8.19
8.96
9.23
6.35
3.38
1.06
9.99
6.16
-4.1
-8.19
-3.83
-6.34
Book Value per Share
- -
5.36
8.16
5.51
3.35
3.94
2.76
4.42
13.84
13.88
-3.39
-3.95
-5.64
-10.11
-2.72
-6.45
Tangible Book Value per Share
- -
9
6
6
7
7
7
9
11
13
18
18
20
22
24
24
Basic Weighted Avg Shares
- -
488
487
523
911
916
834
880
983
1,207
1,356
1,477
1,727
931
969
1,017
Sales/Revenue/Turnover
- -
1.43
0.85
0.42
-0.68
0.85
0.96
-0.86
-3.94
-2.76
-4.76
-8
-11.33
-16.2
-8.52
-10.25
Operating Margin (%)
- -
7
5
5
8
9
7
9
17
19
32
39
51
40
43
46
Depreciation Expense
- -
4
9
6
-15
7
3
-13
-36
-39
-52
-136
-226
-171
82
-97
Net Income, GAAP
- -
22.69
- -
6.29
- -
- -
14.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
0.8
1.78
1.17
-1.7
0.78
0.41
-1.45
-3.69
-3.23
-3.86
-9.19
-13.07
-18.38
8.49
-9.56
Profit Margin (%)
34
31
28
91
63
61
54
21
154
298
215
383
325
155
113
97
Working Capital
8
6
- -
77
58
58
62
9
3
116
349
520
520
493
236
308
LT Debt
90
79
82
86
73
77
73
104
294
444
406
532
485
351
431
340
Total Equity
- -
4.63
- -
1.51
- -
- -
4.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
5.74
- -
5.75
- -
- -
4.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
6.46
13.71
8.8
-24.03
12.14
5.5
-20.91
-76.86
-157.58
-55.26
-93.81
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.88%
-0.72%
-21%
Free Cash Flow
-104.08%
-8.36%
-53.51%
Net Income, GAAP
-46.18%
-32.99%
-218.2%
Sales/Revenue/Turnover
3.22%
-2.24%
4.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
969
2024
- -
- -
- -
- -
1,017
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3.47
2024
- -
- -
- -
- -
-4.06
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
DKSH Holding AG (DKSH.SW)
Wellgistics Health, Inc. (WGRX)
Cencora, Inc. (0HF3.L)
DocMorris AG (ROSE.SW)
Mono Pharmacare Limited (MONOPHARMA.NS)
Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
Business
DocMorris AG operates as a leading European digital health company focused on online pharmacy, marketplace services, and professional health services. The company offers prescription medicines (Rx), over-the-counter (OTC) medicines, consumer health products, beauty and personal care (BPC) items, nutritional supplements, painkillers, first aid products, and private label OTC medicines through its core online pharmacy business; marketplace services providing assortment expansion via over 1,500 pharmacy and seller partners across Europe and fast delivery options including DocMorris Express same-day service; and professional health services encompassing telemedicine via TeleClinic with over 1,500 doctors and 1.6 million treatments delivered, partnerships with pharmaceutical companies for condition-specific digital health journeys on DocMorris Ratgeber, and solutions for health insurers including medication management, automated prescribing, direct billing, and pharmaceutical advice. DocMorris serves more than 10 million active customers primarily in Germany, the Netherlands, Spain, France, Portugal, and Switzerland, with brands such as DocMorris, PromoFarma by DocMorris, and TeleClinic; it generates the majority of revenue from its Germany segment including mail-order pharmacy and services for pharmacies, alongside its Europe segment marketplace operations. Founded in 1993 and headquartered in Frauenfeld, Switzerland, the company, formerly Zur Rose Group, rebranded to DocMorris AG in May 2023 following the sale of its Swiss business to Migros/Medbase to focus on core B2C operations mainly in Germany. Recent developments include a May 2025 annual general meeting approving a CHF 200 million capital increase with subscription rights to fund prescription medicines growth and potential convertible bond repayment, alongside 2024 revenue of CHF 1,085 million with 6.7% growth and accelerated Rx business expansion targeting 50% growth in early 2025; strategic partnerships such as dmr Advertising with LiveRamp and Criteo for retail media, TeleClinic with ADAC for digital healthcare access, and Klarna for payment streamlining; receipt of gematik approval for e-prescription redemption via health card, early redemption of 2025 convertible bonds, and CFO transition to Daniel Wüest; plus sustainability initiatives like reusable packaging testing and marketing campaigns emphasizing e-prescription accessibility.